In a significant development that underscores the evolving sophistication of cancer immunotherapy, Hong Kong-based Antengene Corporation presented compelling clinical data at the J.P. Morgan Healthcare Conference on January 16, 2026, showcasing robust efficacy results for its lead antibody-drug conjugate (ADC) while unveiling an ambitious pipeline of next-
Silexion Therapeutics* stands at the cutting edge of cancer’s final frontier – the notorious KRAS mutation that drives some of medicine’s deadliest tumors. Their groundbreaking SIL-204 therapy isn’t just showing promise; it’s delivering jaw-dropping results with 50% tumor reduction and complete destruction in half of
Silexion Therapeutics’ (NASDAQ: SLXN)* groundbreaking RNAi therapy showing 70-80% tumor reduction takes major step forward with global manufacturing collaboration; Wall Street analysts reportedly maintain $5 price target representing potential 500% upside as company targets $470B precision medicine market In a strategic move that significantly advances its revolutionary cancer treatment
Eli Lilly’s oral GLP-1 breakthrough has sparked even greater interest from the market in the innovative obesity drug sector. Companies like DarioHealth, which provides digital support tools to improve medication adherence, and Viking Therapeutics, with its own GLP-1 pipeline may present unique opportunities to benefit from the
Silexion Therapeutics Corp. (NASDAQ: SLXN)* recently released its full-year 2024 financial results and business update, showcasing remarkable progress in its clinical and preclinical programs targeting KRAS-driven cancers. Following these developments, we spoke with the Chief Financial Officer Mirit Horenshtein Hadar about the company’s achievements and strategic direction.
A newly published study from the Cleveland Clinic’s Lerner Research Institute has added to the growing body of evidence supporting Nuvectis Pharma’s (NASDAQ: NVCT)* NXP900, a novel SRC/YES1 kinase inhibitor. The study, featured in Molecular Cancer Research, demonstrated that the combination of NXP900 with AstraZeneca’s blockbuster
Silexion Therapeutics* (NASDAQ: SLXN) is making strides in oncology with its RNAi-based treatment, SIL-204, targeting KRAS-driven cancers. In an interview on Market Leaders, CEO Ilan Hadar discussed the company’s recent breakthroughs and market activity. During the interview, Hadar highlighted that SIL-204 has shown promising preclinical
DarioHealth (Nasdaq: DRIO)*, a leader in digital health solutions, has taken a bold step into one of healthcare’s fastest-growing markets by enhancing its GLP-1 weight-loss program with virtual prescribing capabilities. The move positions the company to capture a significant share of the weight-loss market, which
Nuvectis Pharma (NASDAQ: NVCT) has reported encouraging interim data from its Phase 1b study of NXP800, a drug candidate designed to treat platinum-resistant, ARID1a-mutated ovarian cancer. This type of cancer is known for its poor prognosis and limited treatment options, so any sign of disease stability or tumor
